OBJECTIVE: To prospectively evaluate the predictive factors for the nonresponse to empirical antibiotic treatment and mortality in patients with intensive care unit-acquired pneumonia. DESIGN: A 1-yr prospective cohort of patients with suspicion of intensive care unit-acquired pneumonia. SETTING: Five medical and surgical intensive care units of Hospital Clinic in Barcelona. PATIENTS: A total of 71 patients with intensive care unit-acquired pneumonia were studied. The definition of nonresponse included at least one of the following: failure to improve the Pao2/Fio2 ratio or need of intubation because of pneumonia, persistence of fever or hypothermia and purulent respiratory secretions, worsening of pulmonary infiltrates, or occurrence of septic shock or multiple organ dysfunction not present at onset of pneumonia. INTERVENTIONS: Clinical assessment, including severity scores, blood and quantitative cultures of respiratory secretions, and cytokine measurements in serum and bronchoalveolar lavage at onset of pneumonia and 72 hrs after antimicrobial treatment. MEASUREMENTS AND RESULTS: A total of 44 patients (62%) fulfilled criteria of nonresponse, and at least one cause of nonresponse could be determined in 28 cases (64%): inappropriate treatment in ten (23%), superinfection in six (14%), concomitant foci of infection in 12 (27%), and noninfectious causes in seven cases (16%). The remaining 16 patients with no definite cause of nonresponse presented with septic shock, multiple organ dysfunction, or acute respiratory distress syndrome. Increased levels of interleukin-6 at onset of pneumonia (odds ratio, 9.7; p =.014) was an independent predictor of nonresponse to treatment. Likewise, increased level of interleukin-6 at follow-up (odds ratio, 27; p =.001) was the only independent predictor for hospital mortality. CONCLUSION: Increased systemic inflammatory response was the main predictor of nonresponse to treatment and mortality.
OBJECTIVE: To prospectively evaluate the predictive factors for the nonresponse to empirical antibiotic treatment and mortality in patients with intensive care unit-acquired pneumonia. DESIGN: A 1-yr prospective cohort of patients with suspicion of intensive care unit-acquired pneumonia. SETTING: Five medical and surgical intensive care units of Hospital Clinic in Barcelona. PATIENTS: A total of 71 patients with intensive care unit-acquired pneumonia were studied. The definition of nonresponse included at least one of the following: failure to improve the Pao2/Fio2 ratio or need of intubation because of pneumonia, persistence of fever or hypothermia and purulent respiratory secretions, worsening of pulmonary infiltrates, or occurrence of septic shock or multiple organ dysfunction not present at onset of pneumonia. INTERVENTIONS: Clinical assessment, including severity scores, blood and quantitative cultures of respiratory secretions, and cytokine measurements in serum and bronchoalveolar lavage at onset of pneumonia and 72 hrs after antimicrobial treatment. MEASUREMENTS AND RESULTS: A total of 44 patients (62%) fulfilled criteria of nonresponse, and at least one cause of nonresponse could be determined in 28 cases (64%): inappropriate treatment in ten (23%), superinfection in six (14%), concomitant foci of infection in 12 (27%), and noninfectious causes in seven cases (16%). The remaining 16 patients with no definite cause of nonresponse presented with septic shock, multiple organ dysfunction, or acute respiratory distress syndrome. Increased levels of interleukin-6 at onset of pneumonia (odds ratio, 9.7; p =.014) was an independent predictor of nonresponse to treatment. Likewise, increased level of interleukin-6 at follow-up (odds ratio, 27; p =.001) was the only independent predictor for hospital mortality. CONCLUSION: Increased systemic inflammatory response was the main predictor of nonresponse to treatment and mortality.
Authors: Marta Di Pasquale; Mariano Esperatti; Ernesto Crisafulli; Miquel Ferrer; Gianluigi Li Bassi; Mariano Rinaudo; Angels Escorsell; Javier Fernandez; Antoni Mas; Francesco Blasi; Antoni Torres Journal: Intensive Care Med Date: 2013-08-02 Impact factor: 17.440
Authors: J Ruiz-Ramos; P Vidal-Cortés; A Díaz-Lamas; R Reig-Valero; F Roche-Campo; M Del Valle-Ortiz; X Nuvials-Casals; M Ortiz-Piquer; D Andaluz-Ojeda; L Tamayo-Lomas; M A Blasco-Navalpotro; M Rodriguez-Aguirregabiria; J Aguado; P Ramirez Journal: Eur J Clin Microbiol Infect Dis Date: 2017-04-04 Impact factor: 3.267
Authors: Bryan D Kraft; Claude A Piantadosi; Ashlee M Benjamin; Joseph E Lucas; Aimee K Zaas; Marisol Betancourt-Quiroz; Christopher W Woods; Alan L Chang; Victor L Roggli; Craig D Marshall; Geoffrey S Ginsburg; Karen Welty-Wolf Journal: Am J Respir Cell Mol Biol Date: 2014-05 Impact factor: 6.914
Authors: Sara Gil-Perotin; Paula Ramirez; Veronica Marti; Jose Miguel Sahuquillo; Eva Gonzalez; Isabel Calleja; Rosario Menendez; Juan Bonastre Journal: Crit Care Date: 2012-05-23 Impact factor: 9.097
Authors: Ignacio Martin-Loeches; Lieuwe D Bos; Pedro Povoa; Paula Ramirez; Marcus J Schultz; Antoni Torres; Antonio Artigas Journal: Intensive Care Med Exp Date: 2015-09-16